Background: Cytidine deaminase (CDA) polymorphisms may affect the response to gemcitabine/cisplatin chemotherapy in patients with non-small cell lung cancer (NSCLC). This study is designed to investigate the associations of CDA-79A>C and 208G>A polymorphisms and gemcitabine/cisplatin chemotherapy effectiveness in Xinjiang Uyghur and Han patients. Methods: This prospective cohort study enrolled consecutive patients with stage IIIb/IV NSCLC administered gemcitabine/cisplatin chemotherapy at the First Affiliated Hospital, Medical College of Shihezi University and the First People's Hospital, Kashgar Region. CDA-A79C and CDA-G208A polymorphisms were detected by direct sequencing. Progression-free survival was analyzed by the Kaplan-Meier method. Associations of A79C and G208A polymorphisms with treatment effectiveness and progression-free survival were analyzed using logistic regression and multivariate Cox regression analyses. Subgroup analyses based on ethnicity were performed. Results: The study enrolled 120 patients. A79C and G208A polymorphisms followed the Hardy-Weinberg equilibrium. The frequencies of the AA, AC, and CC genotypes and the A and C alleles of A79C were 52.2%, 29.9%, 17.9%, 67.2%, and 32.8%, respectively, in Han patients and 75.4%, 18.9%, 5.7%, 84.9%, and 5.1%, respectively, in Uyghur patients. Uyghur patients had lower frequencies of A79C-AC/CC genotypes, A79C-C allele, G208A-GA genotype, and G208A-A allele (P<0.05). Compared with A79C-AA, the odds of ineffective chemotherapy were increased for A79C-AC (odds ratio [OR] 2.818; 95% confidence interval [95% CI] 1.031, 7.705; P=0.043) and A79C-CC (OR 9.864; 95% CI 1.232, 78.966; P=0.031). G208A polymorphisms did not influence chemotherapy effectiveness. Chemotherapy was more effective in Han patients than in Uyghur patients for A79C-AC and G208A-GG. Progression-free survival was longer for A79C-AA versus A79C-AC/CC (10 vs. 7 months, P=0.004) and G208A-GA/AA vs. G208A-AA (12 vs. 8 months, P=0.010). Polymorphisms of A79C (hazard ratio [HR] 1.617; 95% CI 1.009, 2.592; P=0.046) and G208A (HR 2.193; 95% CI 1.055, 4.557; P=0.035) were associated with progression-free survival. Conclusion: For Uyghur and Han ethnic groups, A79C and G208A polymorphisms can be used as a promising biomarker for the chemotherapy efficacy and prognosis of NSCLC.
Introduction
Lung cancer is one of the main causes of cancer-related deaths worldwide. 1 In the USA, lung cancer ranks second among all cancers for incidence and is predicted to become the most important cause of cancer-related mortality. 2 About 80% of all lung cancers are non-small cell lung cancers (NSCLCs), with lung adenocarcinoma and squamous cell carcinoma (SCC) the most common types. 3, 4 The firstline systemic therapy for locally advanced and metastatic NSCLC is a combination of a platinum-containing agent with a non-platinum-containing agent. 5 Gemcitabine plus cisplatin is among the most commonly used doublet regimens, particularly in patients with SCC of the lung. [6] [7] [8] Gemcitabine is a difluoronucleoside anti-metabolite drug that interferes with cell replication after conversion into active triphosphorylated nucleotides. 9 Clinical observations have indicated that patients with the same pathological type and stage of NSCLC have differing therapeutic responses to the same gemcitabine-containing regimen. The differing responses to treatment may be due to (at least in part) inter-individual variation in gemcitabine pharmacokinetics and pharmacodynamics, which in turn may result from genetic differences among individuals such as single nucleotide polymorphisms (SNPs). 10 Cytidine deaminase (CDA) is a key enzyme involved in the metabolic inactivation of gemcitabine and is encoded by a gene displaying genetic and epigenetic polymorphisms. 11 In particular, two SNPs of CDA (A79C and G208A) have been reported to be associated with the response to therapy with gemcitabine. The 79A>C (Lys27Gln) polymorphism in exon 1 of the CDA gene was associated with reduced deaminase activity in vitro, 12, 13 although it was not found to have a notable effect on gemcitabine pharmacokinetics in patients with NSCLC. 14, 15 Furthermore, there are conflicting data regarding whether SNPs at this locus of CDA affect the response of patients with NSCLC to therapy with gemcitabine/cisplatin. For example, one study described longer time to progression and longer overall survival for the C79C genotype than for the A79A/A79C genotypes, 16 another study reported similar results as well as an association of A79A with grade ⩾3 neutropenia/ thrombocytopenia, 17 and a third study found no significant effects on the response to treatment, hematologic toxicity, or non-hematologic toxicity. 18 The 208G>A (Ala70Thr) SNP of CDA has been reported to decrease the clearance of gemcitabine in patients with NSCLC and to increase the risk of grade ⩾3 neutropenia. 14, 19 Importantly, the frequencies of the CDA mutant alleles vary between different countries, regions, and ethnic groups. For example, the reported allele frequencies of CDA 79A>C were 0.36-0.41 in European Caucasians, 0.30 in Caucasian Americans, 0.20 in Japanese, 0.11 in African Americans, and 0.04 in Africans. 12, 14, 15, 17, 18, 20, 21 The allele frequencies of CDA 208G>A have been reported to be around 0.04 in Japanese, 14, 20 but this SNP has not been detected in Caucasians. 22 This raises the possibility that the allele frequencies of the 79A>C and 208G>A polymorphisms may vary between ethnic groups in China, potentially influencing the response to therapy with gemcitabine/cisplatin.
We hypothesized that the distributions of CDA 79A>C and CDA 208G>A would differ between Xinjiang Uyghur and Han people. Therefore, the aims of this study were to compare the genotype distributions of the 79A>C and 208G>A polymorphisms of the CDA gene in Xinjiang Uyghur and Han patients with NSCLC and to explore the associations of these SNPs with the effectiveness of chemotherapy with gemcitabine/cisplatin.
Materials and methods

Study participants
This prospective cohort study enrolled consecutive patients with inoperable NSCLC seen at the First Affiliated Hospital of the Medical College of Shihezi University (Xinjiang, China) and the First People's Hospital of Kashgar Region (Xinjiang, China) between August 2014 and April 2016. Patients meeting the following criteria were enrolled: (a) age ⩾18 years; (b) residents of the Uyghur or Han region with no blood relationship with each other; (c) diagnosed with stage IIIB or IV NSCLC based on tumor cytology or histology; (d) no history of interracial marriage; (e) not previously treated with chemotherapy; (f) adequate bone marrow reserve (based on leukocyte and platelet counts); (g) adequate liver function (based on alanine transaminase, aspartate transaminase, and bilirubin levels); and (h) adequate renal function (based on estimated glomerular filtration rate).
The exclusion criteria were: (a) unclear diagnosis; (b) active infection; (c) presence of another primary malignancy; (d) severe organ dysfunction (including severe dysfunction of the cardiovascular, hepatic, or renal systems); (e) uncontrolled hypercalcemia; and (f) symptomatic brain metastases.
The study was approved by the Ethics Committee of the First Affiliated Hospital of Medical College of Shihezi University. All patients provided informed written consent before inclusion in the study and the administration of chemotherapy.
Collection of baseline clinical data
The following clinical data were recorded: age, gender, pathological type of NSCLC (adenocarcinoma or SCC), tumor node metastasis stage, and Eastern Cooperative Oncology Group performance status (ECOG PS) score.
DNA extraction
Genomic DNA was isolated from 3 mL of peripheral blood sample using the TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd., Beijing, China) following the manufacturer's guidelines. The yield and quality of DNA samples were evaluated using a Nanodrop Spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA). Samples with the A260/A280 ratio falling within the range of 1.8-2.0 were determined to be of good quality.
Polymerase chain reaction amplification. Polymerase chain reaction (PCR) was performed using 2×Taq PCR Master Mix (Shenggong Biological Engineering Co. Ltd., Shanghai, China) and a 7500 Fast Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, USA). Based on information in the published literature, the following primers were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA, USA) and synthesized and purified by Shenggong Biological Engineering Co. (a) A79C upstream primer, 5′-GTAGCTTC-CTTCCAGTAGCGTG-3′; downstream primer, 5′-CTGC CTTCCTGTACATCT-3′; amplified product, 543 bp; (b) G208A upstream primer, 5′-GACAGTGCCAGTTCTG GG-3′; downstream primer, 5′-CTGCAGGATAGTCC-3′; amplified product, 300 bp. The PCR cycling conditions for the A79C locus were as follows: pre-denaturation at 95°C for 5 min; 35 cycles of denaturation at 94°C for 10 s, annealing at 60°C for 10 s, and extension at 72°C for 30 s; extension at 72°C for 5 min; and storage at 4°C. The amplification conditions for the G2081A locus were: predenaturation at 95°C for 5 min; 35 cycles of denaturation at 94°C for 10 s, annealing at 70°C for 10 s and extension at 72°C for 30 s; extension at 72°C for 5 min; and storage at 4°C.The PCR products were subjected to 2% agarose gel electrophoresis (Bio-Rad Laboratories), stained with Goldview Nucleic Acid Dye (Solarbio Life Sciences, Beijing, China) and photographed using an ultraviolet gel imaging system (Bio-Rad Laboratories).
Sequencing analysis
The PCR products obtained by agarose gel electrophoresis were sent to Biomed Gene Technology (Beijing, China) for sequencing. The gene sequence was read by Chromas software, and the CDA gene A79C and G2081A loci were read.
Chemotherapy
All patients received the same chemotherapy regimen given in 21-day cycles: intravenous (IV) infusion of gemcitabine 1000 mg/m 2 on days 1 and 8, and IV infusion of cisplatin 75 mg/m 2 on days 1-2. Patients who experienced complications during chemotherapy were unable to tolerate chemotherapy or who refused chemotherapy were excluded from the analysis.
Evaluation of the response to chemotherapy
Follow-up was carried out up to 30 October 2016, and all patients were followed for > 6 months. The response to chemotherapy after two cycles was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. 23 The tumor response was classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The specific efficacy evaluation criteria are as follows: CR: all target lesions disappeared and lasted for more than 4 weeks; PR: the sum of the maximum diameter of the tumor is reduced by at least 30% and maintained for more than 4 weeks; PD: the total length of the original target lesion is increased by more than 20% and the absolute value of the original target lesion is increased by more than 5 mm; SD: the total length of the baseline lesions is reduced but not up to PR, or increased but not up to PD. Chemotherapy was defined as effective in patients with CR, PR, or SD, and ineffective in patients with PD.
Statistical analysis
The data were analyzed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). The relationships between the clinicopathological features and chemotherapy effectiveness were analyzed using the chi-squared test. This test was used to examine the A79C and G208A loci in the enrolled population to determine whether the polymorphisms followed the Hardy-Weinberg equilibrium. The genotype frequencies in the two ethnic groups were evaluated using the chi-squared test. A logistic regression model was constructed to analyze the associations between the various genotypes of each locus and the effectiveness of chemotherapy, with the calculation of odds ratios (ORs) and 95% confidence intervals (95% CIs). Progression-free survival (PFS) was assessed using Kaplan-Meier survival curves and the log-rank test. Multivariate Cox regression analysis was carried out to identify polymorphisms associated with PFS, and hazard ratios (HRs) and 95% CIs were calculated. P < 0.05 was taken to indicate statistical significance.
Results
Baseline clinical characteristics of the study participants
A total of 120 patients (65 males) with a median age of 63 years (range, 33-77 years) were enrolled in the study, including 53 Uyghur patients and 67 Han patients. The NSCLC was SCC in 69 cases and adenocarcinoma in 51 cases, and the clinical stage was IIIB in 60 cases and stage IV in 60 cases. The ECOG PS score was 0-1 point in 84 cases and 2 points in 36 cases. There were no significant differences between Xinjiang Uyghur patients and Han patients in any of the baseline clinical characteristics ( Table 1) .
Hardy-Weinberg equilibrium
Both the A79C and G208A polymorphisms followed the Hardy-Weinberg equilibrium (P > 0.05, chi-squared test; Supplementary Table 1 ).
Comparison of the genotype and allele frequencies of A79C and G208A between Uyghur and Han patients with NSCLC
In Han patients, the frequencies of the wild-type homozygous genotype (AA), heterozygous genotype (AC) and mutant homozygous genotype (CC) were 35/67 (52.2%), 20/67 (29.9%), and 12/67 (17.9%), respectively, and the frequencies of the A and C alleles were 90/134 (67.2%), and 44/134 (32.8%), respectively. In Xinjiang Uyghur patients, the AA, AC, and CC genotype frequencies were 40/53 (75.4%), 10/53 (18.9%), and 3/53 (5.7%), respectively, and the frequencies of the A and C alleles were 90/106 (84.9%) and 16/106 (5.1%), respectively. There were statistically significant differences between the two ethnic groups in genotype frequencies (P = 0.02) and allele frequencies (P = 0.002), with Xinjiang Uyghur patients having lower frequencies of the AC/CC genotypes and C alleles ( Table 2 ).
There were statistically significant differences in genotype frequencies (P = 0.011) and allele frequencies (P = 0.015) between the ethnic groups, with Xinjiang Uyghur patients having lower frequencies of the GA genotype and the A allele ( Table 2 ).
Associations between A79C and G208A gene polymorphisms and chemotherapy effectiveness in all patients
When all patients were considered together, chemotherapy was effective in 48/75 (64.0%) of those with the AA genotype of A79C, 10/30 (33.3%) of those with the AC genotype of A79C, and 3/15 (20.0%) of those with the CC genotype of A79C (Table 3 ). Regression analysis revealed that, compared with the wild-type AA genotype of A79C, the odds of ineffective chemotherapy were increased for the AC genotype (OR 2.818; 95% CI 1.031, 7.705; P = 0.043) and CC genotype (OR 9.864; 95% CI 1.232, 78.966; P = 0.031). However, there were no significant differences in the rates of effective chemotherapy between the various genotypes of G208A (Table 3 ).
Associations between A79C and G208A gene polymorphisms and chemotherapy effectiveness in Han patients and Uyghur patients
When Han patients and Uyghur patients were considered as separate groups, significant differences in chemotherapy effectiveness were observed between the AA, AC, and CC genotypes, with the rate of ineffective chemotherapy highest for the AA genotype and lowest for the CC genotype in both ethnic groups (Supplementary Table 2 ). By contrast, the G208A genotype was without significant influence on chemotherapy effectiveness in both Han patients and Uyghur patients.
Comparisons of chemotherapy effectiveness between Han patients and Uyghur patients with the same genotype
revealed that the AC genotype of A79C was associated with a significantly higher rate of chemotherapy effectiveness in Han patients (35.0% vs. 30.0%) and that the GG genotype of G208A was also associated with a significantly higher rate of chemotherapy effectiveness in Han patients (55.8% vs. 32.0%). However, there were no significant differences in chemotherapy effectiveness between the two ethnic groups for the other genotypes of A79C and G208A.
Associations between A79C and G208A gene polymorphisms and PFS
When all patients were analyzed together, PFS was significantly longer in those with the AA genotype of A79C than in those with the AC+CC genotypes (10 months vs. 7 months, P = 0.004; Figure 1(a) ). Furthermore, PFS was also significantly longer in those with the GA+AA genotypes of G208A than in those with the AA genotype (12 months vs. 8 months, P = 0.010; Figure 1(b) ).
Multivariate regression analysis revealed that the A79C genotype of CDA (AA vs. AC+CC, HR 1.617; 95% CI 1.009, 2.592; P = 0.046) and the G208A genotype of CDA (GA+AA vs. GG, HR 2.193; 95% CI 1.055, 4.557; P = 0.035) were significantly associated with PFS (Table  4 ). However, gender, histopathologic type, clinical stage and ECOG PS score were not significantly associated with PFS (Table 4 ).
Discussion
A notable finding of the present study was that the frequencies of the AC/CC genotypes of A79C, the C allele of A79C, the GA genotype of G208A, and the A allele of G208A were lower for Xinjiang Uyghur patients than for Han patients with NSCLC. Furthermore, the odds of ineffective chemotherapy were increased for the AC and CC genotypes of A79C as compared with the AA genotype, whereas G208A polymorphisms did not influence chemotherapy effectiveness after two cycles. Importantly, chemotherapy was more effective in Han patients than in Uyghur patients for the A79C AC genotype and the G208A GG genotype. Additionally, PFS was longer for the A79C AA genotype than for the AC/CC genotype, and longer for the G208A GA/AA genotype than for the AA genotype. Moreover, polymorphisms of A79C and G208A were associated with PFS. Taken together, our findings indicate that the distributions of A79C and G208A polymorphisms differed between Uyghur and Han ethnic groups and that polymorphisms at these two loci were associated with the response to gemcitabine chemotherapy. CDA is a key enzyme in the metabolism of gemcitabine. After gemcitabine enters the body, CDA deaminates 90% of its metabolites to inactive products in the plasma that are subsequently excreted. A79C and G208A polymorphisms are thought to affect the activity of CDA through changes in its expression and structure, and in turn this might influence the response to chemotherapy with gemcitabine. [11] [12] [13] Indeed, studies have shown that CDA A79C and gene polymorphisms are associated with the toxicity of chemotherapy, resulting in increased occurrence of adverse reactions after the administration of gemcitabine 14, 17, 19, 24, 25 or cytarabine. 26 Previous studies have reported large differences in the allele frequencies of CDA 79A>C between European Caucasians (0.36-0.41), Caucasian Americans (0.30), Japanese (0.20), African Americans (0.11), and Africans (0.04). 12, 14, 15, 17, 18, 20, 21 Consistent with the above research, Carpi et al. 27 found substantial variations in the frequencies of the CDA 79A>C SNP between ethnicities, with the highest frequency in Caucasians (35.9%) and the lowest in Africans (9.7%). Sugiyama et al. 28 determined that the frequencies of 79A>C were 0.327 in Caucasian Americans, 0.204 in Japanese, 0.155 in Chinese Americans, 0.153 in Koreans, and 0.087 in African Americans, while the frequencies of 208G>A were 0.005 in Koreans and 0.022 in Japanese, with the minor allele not detected in Chinese Americans, Caucasian Americans, or African Americans. In the present study, the polymorphisms of A79C and G208A followed the Hardy-Weinberg equilibrium, suggesting that both CDA gene polymorphisms can be stably inherited among different ethnic groups. The A79C mutation frequency was 47.8% and the mutant allele frequency was 32.8% in Han patients, compared with values of 24.6% and 5.1% in Uyghur patients. Additionally, the G208A mutation frequency was 22.4% and the mutant allele frequency was 11.2% in Han patients, compared with 5.7% and 2.8%, respectively, in Uyghur patients. Thus, there were significant differences between the Han and Uyghur ethnic groups in the distribution of CDA polymorphisms at these two loci.
Since mutations of the CDA gene can alter the functional activity of CDA, this will ultimately affect the efficacy and safety of gemcitabine in patients. Toffalorio et al. 29 identified a correlation between the CDA A79C polymorphism and gene expression levels, with patients carrying wild-type genes (AA) having lower CDA activity than patients carrying mutant genes (AC and CC). Studies by Tibaldi et al. 16, 17 found that patients with low CDA activity showed a better response to gemcitabine chemotherapy, longer PFS, and longer overall survival than patients with a high CDA activity. Also, it has been reported that the wild-type A79C genotype is associated with a lower incidence of severe anemia in patients treated with gemcitabine. 30 Most evaluations of G208A polymorphisms have focused on the adverse effects of gemcitabine, with 208G>A reported to reduce gemcitabine clearance and increase the risk of grade ⩾3 neutropenia. 14, 19 The results of the present investigation are broadly consistent with the findings of the above-mentioned studies. Although the effectiveness of gemcitabine/cisplatin chemotherapy was not affected by G208A polymorphisms, it varied significantly between A79C polymorphisms. The rate of effective chemotherapy was significantly higher for the AA genotype of A79C than for the AC and CC genotypes in both Xinjiang Uyghur and Han patients. Furthermore, the odds of ineffective chemotherapy were around 2.8 and 9.7 times higher for the AC and CC genotypes, respectively, than for the AA genotype. In addition, the PFS of patients with the AA genotype of A79C was significantly longer than that of patients with the AC+CC genotypes (10 months vs. 7 months). Based on these data, we speculate that CDA A79C genotype could be used as an indicator to predict the response of patients with advanced NSCLC to gemcitabine chemotherapy. Since the distribution of A79C genotypes varied between Xinjiang Uyghur and Han patients with NSCLC, these two ethnic groups might show slightly differing responses to gemcitabine chemotherapy. Interestingly, although the rate of effective chemotherapy was not influenced by G208A polymorphisms, PFS was longer in patients with the GA+AA genotype of G208A than in patients with the AA genotype (12 months vs. 8 months). One possible reason for this apparent discrepancy is that chemotherapy effectiveness was measured after two cycles, whereas PFS reflected a longer-term outcome. Thus, it may be that G208A polymorphisms are associated with long-term responses to chemotherapy. However, other possible reasons for this apparent discrepancy cannot be excluded.
This study has some limitations. First, this was only a two-center study, so the generalizability of the findings is not known. Second, the sample size was small, so the study may have been underpowered to detect some real differences between groups. Third, the detection of CDA polymorphisms was based on the analysis of blood samples, for which the rate of false negatives may be higher than that for tissue samples; this may have introduced some bias. Fourth, the effectiveness of chemotherapy was assessed at only one time point (after two cycles), so data for longer-term effectiveness were not available. Fifth, only one chemotherapy regimen was evaluated, so the effects of CDA gene polymorphisms on the response to treatment with other regimens remain uncharacterized. Sixth, data for overall survival were not analyzed. Seventh, the influence of CDA gene polymorphism on the adverse effects of chemotherapy were not determined. Multicenter, prospective studies with larger sample sizes and longer follow-up are needed to confirm and extend our findings.
In conclusion, the distributions of the A79C and G208A polymorphisms of the CDA gene differed between Uyghur and Han ethnic groups. Furthermore, polymorphisms at the A79C locus were associated with the response to chemotherapy with gemcitabine and cisplatin.
